Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to $9.6 million.

  • Mirum Pharmaceuticals' Gains from Investment Securities fell 35.14% to $478,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 70.11%. This contributed to the annual value of $9.6 million for FY2024, which is 813.95% up from last year.
  • Mirum Pharmaceuticals' Gains from Investment Securities amounted to $9.6 million in FY2024, which was up 813.95% from $1.1 million recorded in FY2023.
  • In the past 5 years, Mirum Pharmaceuticals' Gains from Investment Securities ranged from a high of $9.6 million in FY2024 and a low of $1.1 million during FY2023.
  • Over the past 3 years, Mirum Pharmaceuticals' median Gains from Investment Securities value was $3.5 million (recorded in 2022), while the average stood at $4.7 million.
  • In the last 5 years, Mirum Pharmaceuticals' Gains from Investment Securities slumped by 69.95% in 2023 and then spiked by 813.95% in 2024.
  • Mirum Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $5.1 million in 2020, then skyrocketed by 35.47% to $6.9 million in 2021, then crashed by 48.94% to $3.5 million in 2022, then tumbled by 69.95% to $1.1 million in 2023, then skyrocketed by 813.95% to $9.6 million in 2024.